The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Wednesday.
In morning trade the dendrimer products developer’s shares are up 3% to $1.36.
Why is the Starpharma share price pushing higher?
Investors have been buying Starpharma’s shares after it announced that its VivaGel BV product has been launched in the United Kingdom under the brand Betafem BV Gel.
VivaGel BV is a novel, non-antibiotic therapy for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV.
BV is the most common vaginal condition worldwide and twice as common as thrush. One in three women will experience BV and half of these women will have recurrent BV.
Today’s news follows the first European launches of the product in June 2019, including in Germany and other countries. It is available over-the-counter in Europe, without the need to see a doctor or obtain a prescription.
Management notes that Europe represents a large commercial opportunity for VivaGel BV, with access to more than 260 million women.
Dr Jackie Fairley, Starpharma CEO, said: “We are delighted to see VivaGel BV launched in the UK. Starpharma and Mundipharma are working closely together to bring this breakthrough product to European women suffering from BV. We look forward to working with Mundipharma on further registrations and launches across the globe.”
Mundipharma’s CEO, Raman Singh, also spoke positively of the launch.
Singh said: “VivaGel BV is an important addition to the Betadine product portfolio, which continues to evolve to support women’s everyday health and well-being around the world. Together with Starpharma we look forward to realising our joint ambition for Betafe and women’s health.”
The two parties are not resting on their laurels, though. The release explains that they continue to work proactively on regulatory and roll-out activities of VivaGel BV across other Mundipharma’s regions.
The post Starpharma share price charges higher on UK VivaGel BV launch appeared first on Motley Fool Australia.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019